Researchers at the University of Oxford have carried out the world’s first gene therapy operation to tackle the root cause of age-related macular degeneration (AMD). An 80-year-old woman with AMD is the first of ten people to receive the treatment. The procedure was carried out at the John Radcliffe Hospital by Professor Robert MacLaren, Professor [Read More]
News
What is Artificial Intelligence and How Can It Help Me?
by Dan Roberts Artificial intelligence (AI) makes it possible for machines to learn from experience, adjust to new inputs, and perform human-like tasks. It provides us with human-like interactions with computers and helps us with difficult decision making. AI works by super-speed processing of large amounts of information (data), allowing the software to learn automatically [Read More]
New Findings in Genetic Pathologies of AMD
With recent successes in gene replacement therapy, scientists are enthused about studying how genetic variants play a part in age-related macular degeneration (AMD). Previous research has identified 34 small genomic regions (“loci”) on the DNA molecule and 52 genetic variants (mutations) within those loci that are associated with AMD. Variants can regulate certain genes to [Read More]
Bausch + Lomb Launches New Website to Help People Living With AMD
New Website offers Patients Comprehensive, Educational Resources to Navigate Life with Age-Related Macular Degeneration Bausch + Lomb, a leading global eye health company, has announced the launch of SightMatters.com, a new educational online resource for people living with age-related macular degeneration (AMD). Bausch + Lomb launched the site to coincide with the start of AMD [Read More]
Study Finds That Anti-VEGF Drug Treatments For Wet AMD Do Not Cause Strokes
Three anti-VEGF drugs are in clinical use for treatment of wet age-related macular degeneration (wAMD). These are Lucentis (ranibizumab), off-label Avastin (bevacizumab), and Eylea (ranibizumab). The rate of stroke from intravitreal injections of Lucentis was found in the early clinical trials to be 0.2% (1 of 525) in the combined group of patients compared to [Read More]